CRISPR Therapeutics
56.25
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About CRISPR Therapeutics
CRISPR Treateutics AG是一家基因编辑公司，利用其专有的CRISPR/Cas9平台从事严重疾病基于基因的变革性药物的开发。它的CRISPR/Cas9平台是一种基因编辑技术，允许对基因组DNA进行精确的、定向的改变。该公司提供涵盖广泛疾病领域的治疗方案组合，包括血红蛋白病、肿瘤学、再生医学和罕见疾病。该公司由罗杰·诺瓦克、伊曼纽尔·查彭蒂埃、肖恩·帕特里克·福伊、马修·波特乌斯、丹尼尔·安德森、查德·考恩和克雷格·梅洛于2013年10月31日创立，总部设在瑞士祖格。
Trade GPT
Similar Stocks
© 2025 Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.